Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07824323) titled 'Early Triple Lipid-Lowering Therapy With Bempedoic Acid After Acute Coronary Syndrome' on Sept. 11.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).
Primary Sponsor: Taipei Medical University Hospital
Condition:
Acute Coronary Syndromes
Dyslipidemia
Intervention:
Drug: bempedoic acid
Drug: Ezetimibe
Recruitment Status: Recruiting
Phase: Phase 4
Date of First Enrollment: August 26, 2026
Target Sample Size: 400
Countries of Recruitment:
Taiwan
To know more, visit https://clinicaltri...